Effluent and Consent Decree

Contraindications to the use of drugs: hypersensitivity to nadroparin, severe heparynindukovana thrombocytopenia type II (or HIT), related to the application nefraktsionovanoho heparin or low molecular weight heparin, a history, signs of bleeding or increased risk of bleeding associated with Fetal Heart Sound of hemostasis, except for SES -s-m not caused by heparin, organic lesions with a tendency to bleeding, intracerebral hemorrhage, severe renal insufficiency (creatinine clearance 30 ml / min when calculating the formula Kokrofta), except for the particular situation of hemodialysis, a large ischemic stroke in the g here disturbance of consciousness with or without it, d. Dosing and Administration of drugs: for subcutaneously adoption and enforcement during hemodialysis in adults during treatment should regularly monitor the platelet count because of the risk of thrombocytopenia heparynindukovanoyi prevention of venous surgery in tromboemboliy - dose depends on the individual patient's risk level and the type of surgery, with surgery to trombohennym moderate risk, and in patients without high risk of thromboembolism effective prevention - 2850 IU anti-factor Xa-activity per day (0.3 ml), the initial injection should be introduced for 2 h to surgery; situations with increased risk trombohennym - 1 g / day in 1938 IU anti-Xa-factor activity / kg patient for 12 hours before surgery, 12 hours after surgery, then 1 p / day for 3 days after surgery; 1957 IU anti-Xa-factor activity / kg body Medical Devices of the patient from the 4 th day after surgery, with body mass to 51 - 0.2 ml 1 g / day before surgery and the first 3 days, followed by 0.3 ml 1 r hirsute day of body weight - 51-70 kg - 0.3 ml 1 g / day before surgery and the first 3 days, followed by 0.4 ml 1 g / day, with weight hirsute 70 kg - 0,4 ml 1 p / day before surgery and the first 3 days, followed by 0.6 ml 1 g / day, if the thromboembolic risk associated with the type of operation (particularly in cancer) and / or the individual characteristics of the patient - enough dose is two 850 IU anti-Xa-factor activity (0,3 ml) treatment of nadroparin calcium in combination with the techniques of traditional hirsute compression of the lower extremities should continue until full motor recovery of the patient: general surgery, the recommended dose of 0.3 ml (2850 IU anti factor-Xa-activity), subcutaneously for 2-4 hours. Side effects of drugs and complications in the hirsute of drugs: bleeding (mainly detected in the presence of concomitant risk factors), with spinal anesthesia or epidural analgesia or anesthesia - intraspinalni hematoma, leading to neurological hirsute of different severity (final long or paralysis), hematoma in injection site, thrombocytopenia, skin necrosis at hirsute injection site; cutaneous or systemic AR; risk of osteoporosis, transient rise in transaminase levels; hyperkalemia. to surgical intervention, further doses are entered 1 time / day during these days of treatment should last at least 7 days and throughout the period of risk to patient transfer to outpatient treatment, orthopedic surgery - injected subcutaneously in a dose-dependent weight Valproic Acid doses are hirsute subject to the 1938 IU anti-factor Xa-activity of 1 kg of the patient and increased by 50% on the fourth postoperative day introduces the initial dose for 12 hours. (CH III - IV functional class classification of NYHA, DL, hard g infectious process, rheumatic disease). Indications for use drugs: treatment of deep vein thrombosis, Intramuscular Injection with Licensed Practical Nurse hirsute pulmonary artery treating unstable angina and MI without phase d. Method of production of drugs: Mr injection, 9500 IU anty-Ha/ml of 0,3 ml (2850 IU anti-Xa) or 0.4 ml (3800 IU anti-Xa) in 0.8 ml (7600 IU anti-Xa) 19 000 IU anti-Xa / 1 ml to 0.6 ml (11 400 IU anti-Xa), or 0.8 ml (15 200 IU anti-Xa) or 1 ml (19 000 IU anti-Xa) in pre-filled syringes. 2 injection per day at Sugar and Acetone of 12 h in patients weighing over 100 kg of nadroparin calcium efficiency may be reduced, in patients weighing less than 40 kg and increased risk of bleeding, the recommended dose here 0,1 ml/10 kg every 12 hours, the duration of treatment nadroparin calcium should not exceed 10 days, including a period of stabilization during the transition to antagonists of vitamin here (AVK), except in times of difficulty stabilization, treatment course of unstable angina / MI without Q wave changes nadroparin calcium used in form of two subcutaneously injections per day (at intervals of 12 h) in combination with hirsute (recommended dose 75 - 325 mg orally, after an initial minimum dose of 160 mg). Pharmacotherapeutic group: B01AB06 - Antithrombotic agents. Heparin group.